Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers

• DOI: 10.3346/jkms.2022.37.e135
• Publication Date: 2022-04-21T07:42:39Z
• Authors: Seok Ryun Kwon; Namhee Kim; Hyunwoong Park; Dohsik Minn; Seungman Park; Eun Youn Roh; Jong Hyun Yoon; Sue Shin
• Keywords: 0301 basic medicine; Vaccines, Synthetic; 0303 health sciences; COVID-19 Vaccines; SARS-CoV-2; Health Personnel; COVID-19; Brief Communication; Antibodies, Viral; 3. Good health; 03 medical and health sciences; Antibody Formation; Humans; mRNA Vaccines; BNT162 Vaccine

Despite strict guidelines for coronavirus disease 2019 (COVID-19), South Korea is facing its fourth pandemic wave. In this study, by using an automated electrochemiluminescence immunoassay assay, we tracked anti-spike protein receptor-binding domain (anti-S-RBD) antibody titer from the second dose to 2 weeks after the booster dose vaccination. After the second dose, 234 participants had their anti-S-RBD antibody titers decrease over time. We also showed the booster dose (the third dose) increased antibody titer by average 14 (min-max, 2-255)-fold higher compared to the second dose among the 211-booster group participants, therefore, the booster dose could be recommended for low responders to the second dose. Our findings showed a distinct humoral response after booster doses of BNT162b2 mRNA vaccines and may provide further evidence of booster vaccination efficacy. These data will also be helpful in vaccination policy decisions that determine the need for the booster dose.